Insulin-Like Growth Factor 2 Silencing Restores Taxol Sensitivity in Drug Resistant Ovarian Cancer
Brouwer-Visser J, Lee J, McCullagh K, Cossio MJ, Wang Y, Huang GS. Insulin-Like Growth Factor 2 Silencing Restores Taxol Sensitivity in Drug Resistant Ovarian Cancer. PLOS ONE 2014, 9: e100165. PMID: 24932685, PMCID: PMC4059749, DOI: 10.1371/journal.pone.0100165.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Agents, PhytogenicApoptosisBlotting, WesternCell CycleCell ProliferationCystadenocarcinoma, SerousDrug Resistance, NeoplasmFemaleHumansInsulin-Like Growth Factor IInsulin-Like Growth Factor IIMiceMice, NudeOvarian NeoplasmsPaclitaxelPhosphorylationReal-Time Polymerase Chain ReactionReceptor, IGF Type 1Reverse Transcriptase Polymerase Chain ReactionRNA, MessengerRNA, Small InterferingSignal TransductionTumor Cells, CulturedXenograft Model Antitumor AssaysConceptsDrug-resistant ovarian cancerResistant ovarian cancerInsulin-like growth factorIGF2 knockdownOvarian cancerPotential therapeutic targetDrug resistanceTherapeutic targetCell linesOvarian cancer xenograft modelDrug-sensitive cell linesOvarian cancer cohortTaxol sensitivityOvarian cancer cell linesCancer xenograft modelExtreme drug resistanceDose of TaxolDrug-resistant cellsCancer Genome Atlas (TCGA) dataNovel potential targetSensitive cell linesCancer cell linesShort hairpin RNAClinical indicatorsCancer cohort
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply